NasdaqGM:PRCT
NasdaqGM:PRCTMedical Equipment

Why PROCEPT BioRobotics (PRCT) Is Up 8.3% After Raising 2025 Revenue Guidance

Earlier this month, PROCEPT BioRobotics Corporation reported its second-quarter and first-half 2025 earnings, highlighting sales growth to US$79.18 million for the quarter and a narrowing net loss of US$19.58 million compared to the previous year. The company also raised its full-year 2025 revenue guidance to approximately US$325.5 million, reflecting confidence in sustained sales momentum and operational improvements. We'll now consider how this raised full-year revenue guidance could...
NasdaqGS:TIGO
NasdaqGS:TIGOWireless Telecom

Millicom (TIGO) Is Up 6.2% After Earnings Jump Despite Sales Drop and Higher Dividend

Millicom International Cellular S.A. recently reported its second quarter 2025 results, posting net income of US$676 million and basic earnings per share of US$4.05, despite a year-over-year decrease in sales to US$1.37 billion. This substantial rise in profitability, coupled with the approval of an interim dividend of US$2.50 per share, points to enhanced operational efficiency and strong shareholder returns even as revenues decreased. We’ll explore how robust earnings growth, even...
NYSE:LU
NYSE:LUConsumer Finance

How Lufax Holding's Board Diversity Initiative May Shape Governance and Investor Focus (LU)

On August 14, 2025, Lufax Holding announced that Mr. Weidong Li resigned as independent non-executive director and key committee member, with Ms. Wai Ping Tina Lee appointed as his replacement to bolster board diversity in line with updated governance standards. Ms. Lee brings over four decades of legal and banking experience to the board at a time when regulatory changes are driving greater female representation in corporate leadership. We'll examine how the focus on enhanced board...
NasdaqGS:RNW
NasdaqGS:RNWRenewable Energy

Will ReNew Energy Global’s (RNW) Profit Surge and Capacity Growth Shift Its Clean Power Narrative?

ReNew Energy Global Plc recently reported its first quarter FY26 results, recording INR41.18 billion in revenue and a net profit of INR5.13 billion, both showing significant year-over-year increases. The company's clean power capacity grew by 23% and ReNew surpassed analyst revenue estimates, while also reiterating guidance for continued capacity and operational expansion. We’ll explore how ReNew’s robust profit jump and clean energy capacity growth may shape the company’s longer-term...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

The Bull Case for Oddity Tech (ODD) Could Change Following Raised 2025 Revenue Guidance – Learn Why

Earlier this month, Oddity Tech Ltd. reported second quarter sales of US$241.14 million and net income of US$49.29 million, also raising its full-year 2025 net revenue guidance to a new range of US$799 million to US$804 million. This upward revision to revenue targets following robust quarterly results highlights the company’s confidence in its operating momentum and future demand outlook. We’ll explore how Oddity Tech’s strengthened full-year guidance, reflecting accelerating business...
NYSE:GMED
NYSE:GMEDMedical Equipment

Globus Medical’s Strong Q2 and Buyback Might Change The Case For Investing In GMED

Globus Medical reported strong second-quarter 2025 results, with sales of US$745.34 million and net income of US$202.85 million, along with reaffirmed full-year revenue guidance of US$2.80 billion to US$2.90 billion. The company completed a share buyback of 411,000 shares for US$24.99 million, signaling ongoing confidence in its capital allocation strategy. We’ll now explore how Globus Medical’s robust earnings growth and reaffirmed guidance influence its broader investment narrative. We've...
NasdaqGS:ASND
NasdaqGS:ASNDBiotechs

What Ascendis Pharma (ASND)'s Strong Q2 and H1 Results Reveal About Its Path to Stability

Ascendis Pharma released its second quarter and half-year 2025 financial results, reporting sales of €158.05 million and €259 million, respectively, with both periods showing sharply reduced net losses compared to the previous year. This marked improvement in revenue and narrowing of net loss highlights the company's progress toward greater financial stability and operational efficiency as of June 30, 2025. We'll explore how the substantial year-over-year revenue growth and reduced net loss...
NasdaqGM:HRMY
NasdaqGM:HRMYPharmaceuticals

Harmony Biosciences (HRMY) Is Up 7.8% After Earnings Jump and Revenue Guidance Reaffirmed – What's Changed

Harmony Biosciences Holdings recently reported second-quarter 2025 earnings, revealing net income of US$39.78 million versus US$11.59 million a year earlier and reaffirmed its full-year 2025 revenue guidance of US$820 million to US$860 million. This sharp improvement in earnings and maintained revenue outlook highlights the company’s operational momentum and management’s confidence in its ongoing business performance. With Harmony Biosciences delivering much higher profits and upholding its...